• Mobocertinib gets accelerated approval for adult patients diagnosed with metastatic or locally advanced Non-Small Cell Lung Cancer with EGFR (epidermal growth factor receptor) Exon 20 Insertion.
• Approval was based on the results of the Phase 1/2 trial that demonstrated approximately 1.5 years of median duration of response.

On September 15, 2021, the FDA (Food and Drug Administration) granted accelerated approval to Mobocertinib (sold under the brand name EXKIVITY by Takeda Pharmaceuticals, Inc.) for the treatment of patients suffering from metastatic or loca...

Chronic Graft-Versus-Host Disease Gets a New Treatment: Belumosudil

• Belumosudil got FDA Approval on July 16, 2021, to treat Chronic Graft-Versus-Host Disease (chronic GVHD).
• Eligible patients must be aged at least 12 years and have received two prior systemic therapies.

Patients suffering from Chronic Graft-Versus-Host Disease now have an efficacious treatment option, Belumosudil. On 16th July 2021, US FDA (Food and Drug Administration) approved Belumosudil (marketed by Kadmon Pharmaceuticals LLC under the brand name Rezurock) for the treatment of t...